reports
- ABGSC Financials Research
- Albert Broock
- Magnus Andersson
- Patrik Brattelius
Storebrand ASA: 1 director
A director at Storebrand ASA maiden bought 10,000 shares at 106.500NOK and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- ABGSC Financials Research
- Albert Broock
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Company consensus added
We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK335.00) - Strong start to 2024
The Q1 earnings were above our forecast, even though some of the positive effects were one-offs (manufacturing revenues, among others). We believe Vonjo sales have bottomed out and we should be back at QOQ growth from Q2. The haemophilia franchise enjoyed stronger than expected growth, but some of this was due to phasing between quarters (hence this might hurt Q2 sales slightly). We reiterate our BUY and have increased our target price to SEK335 (320).
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC IT Research
- Øystein Elton Lodgaard
- ABGSC Financials Research
- Jan Erik Gjerland
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC IT Research
- Øystein Elton Lodgaard
- Håkon Astrup
Storebrand (Buy, TP: NOK125.00) - Signs of gradual improvement
Q1 PTP was up 30% YOY, largely driven by strong AUM growth and increased interest rates. The Insurance segment showed signs of improvement after several rounds of repricing in previous quarters, supporting the 2025 financial targets. Following regulatory approval and a 191% Solvency II ratio, Storebrand launched a NOK1.1bn buyback programme. We reiterate our BUY and have raised our target price to NOK125 (120) following ~4% positive EPS revisions for 2025e.
- Rune Majlund Dahl
GN Group (Buy, TP: DKK230.00) - Time to rebuild credibility
We forecast Q1 organic sales growth of 3.0% YOY (consensus 2.8%) and an EBITA margin of 9.7% (consensus 9.6%). We see Hearing as starting well, and despite still-negative growth in Enterprise, we expect unchanged 2024 guidance. The upcoming CMD offers management scope to rebuild credibility, and we expect updated long-term targets to reflect “One-GN”. We reiterate our BUY and have raised our target price to DKK230 (215).
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC IT Research
- Øystein Elton Lodgaard
Danske Bank AS: 1 director
A director at Danske Bank AS sold 60,000 shares at 208.230DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- ABGSC Financials Research
- Jan Erik Gjerland
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 24. april 2024 Indberetning nr. 42/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Med...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 24 April 2024 Notification no. 42/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with th...
- ABGSC IT Research
- Øystein Elton Lodgaard
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 23. april 2024 Indberetning nr. 41/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Med...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.